https://vettapharma.com/pharmaceutical-news/bristol-myers-squibbs-sotyktu-approved-for-active-psoriatic-arthritis-in-europe/ 2026-05-09T05:56:50Z VETTAPHARMA en Bristol Myers Squibb's Sotyktu Approved for Active Psoriatic Arthritis in Europe 2026-05-09T05:56:46Z Blog https://vettapharma.com/pharmaceutical-news/angelini-pharma-acquires-catalyst-for-4-1-billion/ 2026-05-08T13:22:28Z VETTAPHARMA en Angelini Pharma Acquires Catalyst for $4.1 Billion 2026-05-08T13:22:23Z Blog https://vettapharma.com/pharmaceutical-news/eli-lilly-invests-4-5b-in-indiana-for-advanced-medicine-production/ 2026-05-08T12:59:06Z VETTAPHARMA en Eli Lilly Invests $4.5B in Indiana for Advanced Medicine Production 2026-05-08T12:59:01Z Blog https://vettapharma.com/pharmaceutical-news/novartis-launches-new-radioligand-therapy-facility-in-texas/ 2026-05-08T12:46:08Z VETTAPHARMA en Novartis Launches New Radioligand Therapy Facility in Texas 2026-05-08T12:46:03Z Blog https://vettapharma.com/pharmaceutical-news/2253/ 2026-05-07T14:41:49Z VETTAPHARMA en GSK Unveils 70+ Abstracts at ATS 2026: Advances in Respiratory Care 2026-05-07T14:39:48Z Blog https://vettapharma.com/pharmaceutical-news/fda-launches-halo-ai-artificial-intelligence-platform-streamlining-regulatory-processes/ 2026-05-07T14:28:31Z VETTAPHARMA en FDA Launches HALO AI (Artificial Intelligence) Platform: Streamlining Regulatory Processes 2026-05-07T14:28:26Z Blog